5-MAPB

From Wikipedia, the free encyclopedia

Template:Short description Template:Cs1 config Template:Short description Page Template:Infobox drug/styles.css has no content.

Page Module:Infobox/styles.css has no content.

5-MAPB
Lua error in package.lua at line 80: module 'Module:InfoboxImage/data' not found.
Lua error in package.lua at line 80: module 'Module:InfoboxImage/data' not found.
Clinical data
Other names5-(N-Methyl-2-aminopropyl)benzofuran
Routes of
administration		Oral[1]
Drug classSerotonin–norepinephrine–dopamine releasing agent; Serotonin 5-HT1B receptor agonist; Serotonin 5-HT2 receptor agonist
Legal status
Legal statusPage Template:Plainlist/styles.css has no content.
Pharmacokinetic data
Duration of action5–6 hours[1]
Identifiers
  • 1-(Benzofuran-5-yl)-N-methylpropan-2-amine
CAS NumberPage Template:Plainlist/styles.css has no content.
PubChem CIDPage Template:Plainlist/styles.css has no content.
PubChem SIDPage Template:Plainlist/styles.css has no content.
IUPHAR/BPSPage Template:Plainlist/styles.css has no content.
DrugBankPage Template:Plainlist/styles.css has no content.
ChemSpiderPage Template:Plainlist/styles.css has no content.
UNIIPage Template:Plainlist/styles.css has no content.
KEGGPage Template:Plainlist/styles.css has no content.
ChEBIPage Template:Plainlist/styles.css has no content.
ChEMBLPage Template:Plainlist/styles.css has no content.
NIAID ChemDBPage Template:Plainlist/styles.css has no content.
PDB ligandPage Template:Plainlist/styles.css has no content.
CompTox Dashboard (EPA)Page Template:Plainlist/styles.css has no content.
Chemical and physical data
FormulaC12H15NO
Molar mass189.25 g/mol (freebase)
225.7 g/mol (HCl salt) g·mol−1
3D model (JSmol)Page Template:Plainlist/styles.css has no content.
  • CC(NC)CC1=CC(C=CO2)=C2C=C1
  • InChI=1S/C12H15NO/c1-9(13-2)7-10-3-4-12-11(8-10)5-6-14-12/h3-6,8-9,13H,7H2,1-2H3
  • Key:ZOVRTIPCNFERHY-UHFFFAOYSA-N
Data page
Template:Infobox drug/data page link

5-MAPB, also known as 5-(N-methyl-2-aminopropyl)benzofuran, is an entactogen and designer drug of the amphetamine family that is similar to MDMA in its structure and effects.[1][2]

5-MAPB was first encountered as a novel designer drug in 2013 and described in the scientific literature in 2014.[3][4] It has been patented by Tactogen as an entactogen for potential use as a medicine.[5]

Use and effects

5-MAPB is an entactogen[1] and has been described by Matthew Baggott as the MDMA analogue so far known that has the closest effects and so-called "magic" to MDMA itself.[6][7] Other analogues that lack the full quality of MDMA include MBDB, methylone, 6-APDB, 5-APDB, 6-APB, 5-APB, MDAT, and MDAI, among others.[6][7]

In addition to its use on its own, 5-MAPB, along with the related entactogen MDAI, is employed as a component of the MDMA-mimicking Borax combo.[6][8][9]

Interactions

Script error: No such module "Labelled list hatnote".

Pharmacology

Pharmacodynamics

5-MAPB acts as a serotonin–norepinephrine–dopamine releasing agent with EC50Tooltip half-maximal effective concentration values for induction of monoamine release of 64 nM for serotonin, 24 nM for norepinephrine, and 41 nM for dopamine using rat brain synaptosomes.[10][1][11][12] It is also a partial agonist of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors.[10][1][13] In addition, unlike MDMA, it is a potent agonist of the serotonin 5-HT1B receptor.[14]

Monoamine release of 5-MAPB and its enantiomers[5]
Compound SERTTooltip Serotonin transporter NETTooltip Norepinephrine transporter DATTooltip Dopamine transporter DAT/SERT ratio
(S)-5-MAPB 67 ND 258 0.26
75% (S)-5-MAPB 80 ND 632 0.13
(RS)-5-MAPB 90 ND 459 0.20
75% (R)-5-MAPB 122 ND 794 0.15
(R)-5-MAPB 184 ND 1951 0.09
Note: This assay used Chinese hamster ovary (CHO) cells expressing human monoamine transporters rather than the more typical rat brain synaptosomes assay.[5]

5-MAPB has been marketed as a less- or non-neurotoxic alternative to MDMA.[15] However, 5-MAPB has been found to be a dose-dependent serotonergic neurotoxin in rodents similarly to MDMA, and might also be a dopaminergic neurotoxin.[15]

Pharmacokinetics

Little formal knowledge exists on 5-MAPB. It does not form the α-methyldopamine metabolite that contributes to the neurotoxicity of MDMA or MDA.[16][17][18][19] A study in rats indicated that the major metabolites of 5-MAPB are 5-APB and 3-carboxymethyl-4-hydroxymethamphetamine.[20]

History

5-MAPB was first encountered as a novel designer drug in 2013 and described in the scientific literature in 2014.[3][4]

Society and culture

Canada

5-MAPB is not listed itself in the CDSA but since it is structurally related to MDMA it may be considered illegal in Canada, although this has not been tested in court.[21]

China

As of October 2015, 5-MAPB is a controlled substance in China.[22]

Finland

Scheduled in the "government decree on psychoactive substances banned from the consumer market".[23]

Luxembourg

As of July 2021, 5-MAPB is not cited in the list of prohibited substances.[24] Therefore, it is still a legal substance.

United Kingdom

5-MAPB was originally banned in the UK in June 2013 under a Temporary class drug order.[25] On March 5, 2014, the UK Home Office announced that 5-MAPB would be made a class B drug on 10 June 2014 alongside every other benzofuran entactogen and many structurally related drugs.[26]

See also

References

Page Template:Reflist/styles.css has no content.

  1. ^ a b c d e f Page Module:Citation/CS1/styles.css has no content.Oeri HE (May 2021). "Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy". Journal of Psychopharmacology. 35 (5): 512–536. doi:10.1177/0269881120920420. PMC 8155739. PMID 32909493.
  2. ^ Page Module:Citation/CS1/styles.css has no content."Temporary class drug order report on 5-6APB and NBOMe compounds". UK Home Office. 4 June 2013. Retrieved 2013-07-10.
  3. ^ a b Page Module:Citation/CS1/styles.css has no content.King LA (2014). "New phenethylamines in Europe". Drug Test Anal. 6 (7–8): 808–818. doi:10.1002/dta.1570. PMID 24574327.
  4. ^ a b https://isomerdesign.com/bitnest/external/EMCDDA/New-Drugs-In-Europe-2013
  5. ^ a b c Page Template:Citation/styles.css has no content.WO 2021/252538, Baggott M, "Advantageous benzofuran compositions for mental disorders or enhancement", published Script error: No such module "auto date formatter"., assigned to Tactogen Inc. 
  6. ^ a b c Page Module:Citation/CS1/styles.css has no content.Baggott M (23 June 2023). Beyond Ecstasy: Progress in Developing and Understanding a Novel Class of Therapeutic Medicine. PS2023 [Psychedelic Science 2023, June 19–23, 2023, Denver, Colorado]. Denver, CO: Multidisciplinary Association for Psychedelic Studies.
  7. ^ a b Page Module:Citation/CS1/styles.css has no content."Better Than Ecstasy: Progress in Developing a Novel Class of Therapeutic with Matthew Baggott, PhD". YouTube. 6 March 2024. Retrieved 20 November 2024.
  8. ^ Page Module:Citation/CS1/styles.css has no content.Hamilton Morris (28 November 2023). "POD 92: Understanding and Improving MDMA with Dr. Matthew Baggott". The Hamilton Morris Podcast (Podcast). Patreon. Retrieved 30 November 2024.
  9. ^ Page Module:Citation/CS1/styles.css has no content."Borax Combo (Synonyms: Blue Bliss)". naddi.org. National Association of Drug Diversion Investigators (NADDI). 14 December 2022. Retrieved 21 November 2024.
  10. ^ a b Page Module:Citation/CS1/styles.css has no content.Roque Bravo R, Silva JP, Carmo H, Carvalho F, Dias da Silva D (2022). "The Toll of Benzofurans in the Context of Drug Abuse". Handbook of Substance Misuse and Addictions. Cham: Springer International Publishing. p. 1–24. doi:10.1007/978-3-030-67928-6_168-1. ISBN 978-3-030-67928-6.
  11. ^ Page Module:Citation/CS1/styles.css has no content.Brandt SD, Walters HM, Partilla JS, Blough BE, Kavanagh PV, Baumann MH (December 2020). "The psychoactive aminoalkylbenzofuran derivatives, 5-APB and 6-APB, mimic the effects of 3,4-methylenedioxyamphetamine (MDA) on monoamine transmission in male rats". Psychopharmacology (Berl). 237 (12): 3703–3714. doi:10.1007/s00213-020-05648-z. PMC 7686291. PMID 32875347.
  12. ^ Page Module:Citation/CS1/styles.css has no content.Sahai MA, Davidson C, Khelashvili G, Barrese V, Dutta N, Weinstein H, et al. (April 2017). "Combined in vitro and in silico approaches to the assessment of stimulant properties of novel psychoactive substances - The case of the benzofuran 5-MAPB" (PDF). Progress in Neuro-Psychopharmacology & Biological Psychiatry. 75: 1–9. doi:10.1016/j.pnpbp.2016.11.004. PMID 27890676. S2CID 30943496.
  13. ^ Page Module:Citation/CS1/styles.css has no content.Shimshoni JA, Winkler I, Golan E, Nutt D (January 2017). "Neurochemical binding profiles of novel indole and benzofuran MDMA analogues". Naunyn Schmiedebergs Arch Pharmacol. 390 (1): 15–24. doi:10.1007/s00210-016-1297-4. hdl:10044/1/43622. PMID 27650729.
  14. ^ Page Template:Citation/styles.css has no content.US 20230150963, Matthew Baggott, "Advantageous benzofuran compositions for mental disorders or enhancement", published Script error: No such module "auto date formatter"., assigned to Tactogen 
  15. ^ a b Page Module:Citation/CS1/styles.css has no content.Johnson CB, Burroughs RL, Baggott MJ, Davidson CJ, Perrine SA, Baker LE (2022). 314.03 / RR6 - Locomotor stimulant effects and persistent serotonin depletions following [1-Benzofuran-5-yl)-N-methylpropan-2-amine (5-MAPB) treatment in Sprague-Dawley rats. Society for Neuroscience Conference, Nov. 14, 2022, San Diego, CA. 5-MAPB has been marketed as a less neurotoxic analogue of MDMA, but no studies have addressed whether 5-MAPB can cause the long lasting serotonergic changes seen with high or repeated MDMA dosing. [...] Neurochemical analyses indicated a statistically significant reduction in 5‑HT and 5-HIAA in all brain regions assessed 24 hours and two weeks after 6 mg/kg 5‑MAPB, with no statistically significant differences in monoamine levels between 1.2 mg/kg and saline-treated rats. There were also non-significant trends for reductions in striatal dopamine at both time intervals after 6 mg/kg 5-MAPB. These results show that 5-MAPB can dose-dependently produce persistent changes in 5-HT and 5-HIAA that appear analogous to those produced by MDMA.
  16. ^ Page Module:Citation/CS1/styles.css has no content.Shimshoni JA, Winkler I, Golan E, Nutt D (January 2017). "Neurochemical binding profiles of novel indole and benzofuran MDMA analogues". Naunyn-Schmiedeberg's Archives of Pharmacology. 390 (1): 15–24. doi:10.1007/s00210-016-1297-4. hdl:10044/1/43622. PMID 27650729.
  17. ^ Page Module:Citation/CS1/styles.css has no content.McCann UD, Ricaurte GA (April 1991). "Major metabolites of (+/-)3,4-methylenedioxyamphetamine (MDA) do not mediate its toxic effects on brain serotonin neurons". Brain Research. 545 (1–2): 279–282. doi:10.1016/0006-8993(91)91297-E. PMID 1860050. S2CID 2574803.
  18. ^ Page Module:Citation/CS1/styles.css has no content.Miller RT, Lau SS, Monks TJ (April 1997). "2,5-Bis-(glutathion-S-yl)-alpha-methyldopamine, a putative metabolite of (+/-)-3,4-methylenedioxyamphetamine, decreases brain serotonin concentrations". European Journal of Pharmacology. 323 (2–3): 173–180. doi:10.1016/S0014-2999(97)00044-7. PMID 9128836.
  19. ^ Page Module:Citation/CS1/styles.css has no content.Conway EL, Louis WJ, Jarrott B (December 1978). "Acute and chronic administration of alpha-methyldopa: regional levels of endogenous and alpha-methylated catecholamines in rat brain". European Journal of Pharmacology. 52 (3–4): 271–280. doi:10.1016/0014-2999(78)90279-0. PMID 729639.
  20. ^ Page Module:Citation/CS1/styles.css has no content.Welter J, Kavanagh P, Meyer MR, Maurer HH (February 2015). "Benzofuran analogues of amphetamine and methamphetamine: studies on the metabolism and toxicological analysis of 5-APB and 5-MAPB in urine and plasma using GC-MS and LC-(HR)-MS(n) techniques". Analytical and Bioanalytical Chemistry. 407 (5): 1371–1388. doi:10.1007/s00216-014-8360-0. PMID 25471293. S2CID 20653012.
  21. ^ Page Module:Citation/CS1/styles.css has no content."Schedule I". Government Of Canada. 2014-12-12. Archived from the original on 2013-11-22. Retrieved 2014-12-13.
  22. ^ Page Module:Citation/CS1/styles.css has no content."关于印发《非药用类麻醉药品和精神药品列管办法》的通知" [Notice on the issuance of the "Regulations on the Listing of Non-Medicinal Narcotic Drugs and Psychotropic Drugs"] (in Chinese). China Food and Drug Administration. 27 September 2015. Archived from the original on 1 October 2015. Retrieved 1 October 2015.{{cite web}}: CS1 maint: unrecognized language (link)
  23. ^ Page Module:Citation/CS1/styles.css has no content."Valtioneuvoston asetus kuluttajamarkkinoilta kielletyistä psykoaktiivisista aineista | 1130/2014 | Lainsäädäntö | Finlex".
  24. ^ Page Module:Citation/CS1/styles.css has no content."Loi du 19 février 1973 concernant la vente de substances médicamenteuses et la lutte contre la toxicomanie" [Law of February 19, 1973 concerning the sale of medicinal substances and the fight against drug addiction.]. Journal officiel du Grand-Duché de Luxembourg (in French).{{cite web}}: CS1 maint: unrecognized language (link)
  25. ^ Page Module:Citation/CS1/styles.css has no content."'NBOMe' and 'Benzofury' banned". UK Home Office. 2013-06-04. Retrieved 10 April 2014.
  26. ^ Page Module:Citation/CS1/styles.css has no content.UK Home Office (2014-03-05). "The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014". UK Government. Retrieved 2014-03-11.

Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found. Template:Monoamine releasing agents Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found. Template:Monoamine neurotoxins Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found.

Retrieved from "https://cosmopedia.co/index.php?title=5-MAPB&oldid=11951752"